Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) just unveiled an announcement.
Lumos Diagnostics Holdings Ltd, a leader in rapid point-of-care diagnostic technologies, has announced an exclusive U.S. distribution agreement for its FebriDx product with PHASE Scientific. This strategic partnership is expected to enhance Lumos’s market presence in the U.S., potentially improving its operational capabilities and offering significant benefits to its stakeholders.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. The company offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms, focusing on infectious and inflammatory diseases.
Average Trading Volume: 1,019,161
Technical Sentiment Signal: Sell
Current Market Cap: A$21.71M
Find detailed analytics on LDX stock on TipRanks’ Stock Analysis page.